Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CBT-001 in pterygium
NCT05456425Phase 3Active, not recruiting
- Sponsor
- Cloudbreak Pharma
- Start
- Jun 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 3, randomised, double-blind trial of STN1014200 in pterygium (3 arms), sponsored by Cloudbreak Pharma. Primary endpoints: Conjunctival Hyperemia Severity Grade at 3 months and Pterygium Length at 12 months. Started Jun 2022; status: active, not recruiting.
02
Drugs
STN1014200
03
Conditions
pterygium
Beyond the preview
Go deeper on NCT05456425.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05456425.